Breast Cancer Prevention Study: Are Healthy Women Put at Risk by Federally Funded Research? : Hearing Before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, Second Session, October 22, 1992
United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations Subcommittee
U.S. Government Printing Office, 1994 - Breast - 272 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
adjuvant adjuvant tamoxifen APHA BCPT Breast Cancer Action breast cancer prevention Cancer Prevention Trial centers Chairman clinical trials concern developing breast cancer Director disease dose Drug Administration effect of tamoxifen eligible endometrial cancer estrogen evidence exam Food and Drug GREENWALD Gregory Burke healthy women HEALY high risk hormone hot flashes human incidence increased risk informed consent informed consent form liver cancer minority women model informed consent National Cancer Institute National Surgical Adjuvant NSABP Oncology osteoporosis participate patients PAYNE percent physician placebo population postmenopausal postmenopausal women potential premenopausal women prevent breast cancer prevention of breast protocol public health questions rats receiving tamoxifen recruitment reduce reported risk of breast risks and benefits Rodriguez-Trias says side effects statement subcommittee subjects Surgical Adjuvant Breast taking tamoxifen tamoxifen therapy tamoxifen trial tests tion tumors uterine cancer woman women with breast Women's Health